Trial CTSU/NSABP-B-55


A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Type: Treatment
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: Yes
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Darcy Spicer, M.D.
Other Trial Staff:  Richa Aggarwal, D.M., Monica Flores, D.M., Yanli Wang, D.M., Kristy Watkins, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.